Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human-Reference-Cited by-同舟云学术

Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human

Published:2007-12 Issue:11-12 Volume:17 Page:913-918
ISSN:0960-8966
Container-title:Neuromuscular Disorders
language:en
Short-container-title:Neuromuscular Disorders

Author:

Neri Marcella,Torelli Silvia,Brown Sue,Ugo Isabella,Sabatelli Patrizia,Merlini Luciano,Spitali Pietro,Rimessi Paola,Gualandi Francesca,Sewry Caroline,Ferlini Alessandra,Muntoni Francesco

Publisher

Elsevier BV

Subject

Genetics(clinical),Clinical Neurology,Neurology,Pediatrics, Perinatology, and Child Health

Reference35 articles.

1. The structural and functional diversity of dystrophin;Ahn;Nat Genet,1993

2. Molecular, cellular, and pharmacological therapies for Duchenne/Becker muscular dystrophies;Chakkalakal;Faseb J,2005

3. X chromosome-linked muscular dystrophy (mdx) in the mouse;Bulfield;Proc Natl Acad Sci USA,1984

4. The molecular basis of muscular dystrophy in the mdx mouse: a point mutation;Sicinski;Science,1989

5. Viral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advances;Odom;Biochim Biophys Acta,2007

Cited by 139 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase I/II Trial of Brogidirsen: Dual-Targeting Antisense Oligonucleotides for Exon 44 Skipping in Duchenne Muscular Dystrophy;2024-08-30

2. Cell therapy for duchenne muscular dystrophy using induced pluripotent stem cell-derived muscle stem cells and the potential of regenerative rehabilitation;Current Opinion in Biomedical Engineering;2024-06

3. CRISPR-Based Gene Editing Techniques in Pediatric Neurological Disorders;Pediatric Neurology;2024-04

4. Revision of splicing variants in theDMDgene;2024-02-02

5. Clinical Trials of Cell Therapy and Regenerative Medicine in Muscular Dystrophies;Handbook of Stem Cell Applications;2024